NYSE:Immunovant, Inc.

График котировок Immunovant, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/BV 10.57
EV/EBITDA -47.95
EBITDA -0.08
Цена ао 44.1

Основные владельцы

Institutions Объем Доля, %
RTW INVESTMENTS, LLC 7510412 7.67
Ghost Tree Capital, LLC 525000 0.54
Defiance ETFs, LLC 26689 0.03
Invesco Capital Management LLC 394325 0.4
Longwood Capital Partners LLC 250000 0.26
Heptagon Capital Limited 199840 0.2
Bvf Inc 1198427 1.22
Cormorant Asset Management, LLC 1637951 1.67
AlphaCentric Advisors LLC 2150 0
Vivo Capital, LLC 1042460 1.06
Driehaus Capital Management (USVI) LLC 86639 0.09
Parkman Healthcare Partners LLC 150151 0.15
Putnam 225600 0.23
Putnam Investment Management, LLC 118465 0.12
PURA VIDA INVESTMENTS, LLC 270806 0.28
Boston Management and Research 58428 0.06
Principal Global Investors, LLC 134438 0.14
Ikarian Capital, LLC 321887 0.33
Camber Capital Management LLC 438800 0.45
ALPS Advisors Inc 157400 0.16
Pinz Capital Management, LP 199100 0.2
Prudential Retirement Services 65324 0.07
Mangrove Partners 230307 0.24
BlackRock Fund Advisors 2147508 2.19

Содержится в ETF

ETF Доля, % Доходность за год, %
ALPS Medical Breakthroughs ETF 2.47 35.77
Defiance Next Gen SPAC Derived ETF 1.64

Похожие компании

Описание Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.